E-Newsletter - October 2025
Spotlight on Alliance Research


Alliance LauNches Six New Clinical Trials

Several new clinical trials are now open, exploring novel therapies, improved treatment strategies, and innovative approaches to cancer care. From testing new drug combinations for rare and aggressive cancers to evaluating digital health tools that improve access to genetic services, these trials aim to improve outcomes, reduce side effects, and personalize treatment for patients across the lifespan.

Below is a selection of recently launched trials, led by Alliance investigators at cancer centers and community sites around the country, now recruiting participants.

Alliance A092204: Testing the addition of an anti-cancer drug, cabozantinib to the immunotherapy drug cemiplimab (REGN2810), in adolescents and adults with advanced adrenocortical cancer

Bhavana Konda, MD, MPH, of The Ohio State University Comprehensive Cancer Center, leads this clinical trial to explore if using two targeted medications can help slow tumor growth in people with advanced adrenocortical carcinoma (ACC), a rare and aggressive cancer of the adrenal glands.

The trial opened on October 22, 2025, with ClinicalTrials.gov Identifier: NCT06900595. To learn more, visit here. Read the news release. 

Alliance A032302: Docetaxel addition in metastatic castrate-sensitive prostate cancer (ASPIRE)

Deepak Kilari, MD, of Medical College of Wisconsin, leads this phase III trial comparing the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic).

The trial opened on September 29, 2025, with ClinicalTrials.gov Identifier: NCT06931340. To learn more, visit here. Read the news release. 

Alliance A232301: AYA Access Study: An enhanced eHealth and chat-bot enabled delivery model for clinical genetic services in community AYA cancer patients

Angela Bradbury, MD, University of Pennsylvania Abramson Cancer Center, and Tara Henderson, MD, PhD, of Ann & Robert H. Lurie Children’s Hospital of Chicago, lead this phase III trial that compares the use of a digital chatbot enabled intervention to standard remote genetic services for increasing uptake of genetic counseling and testing among adolescents and young adult (AYA) cancer patients.

The trial opened on September 23, 2005, with ClinicalTrials.gov Identifier: NCT07091617. To learn more, visit here. Read the news release. 

Alliance A012303: ShortStop-HER2: Shortened duration of adjuvant therapy in patients with early-stage HER2+ breast cancer who achieve pCR after neoadjuvant chemotherapy with HER2 blockade

Adrienne Waks, MD, of the Dana-Farber Cancer Institute, leads this phase III trial that compares six months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complete response (pCR) after preoperative (neoadjuvant) chemotherapy with trastuzumab.

The trial opened on July 25, 2025, with ClinicalTrials.gov Identifier: NCT06876714. To learn more about ShortStop-HER2, visit here. 

Alliance A032303: GAIN-BCG: Gemcitabine alternating with intravesical BCG randomized against BCG alone for patients with recurrent high grade non-muscle invasive bladder bancer

Eugene Pietzak, MD, of the Memorial Sloan Kettering Cancer Center, leads this phase III trial comparing the effect of adding gemcitabine to intravesical Bacillus Calmette Guerin (BCG) versus intravesical BCG alone in patients with non-muscle invasive bladder cancer that has come back after a period of improvement (recurrent).

The trial opened on June 5, 2025, with the ClinicalTrials.gov Identifier: NCT07000084. To learn more, visit here.

Alliance A222301: High-dose prophylactic gabapentin (HOPE) to prevent opioid use for oral mucositis pain during head and neck chemoradiotherapy: A phase III clinical trial

Anurag Singh, MD, of the Roswell Park Comprehensive Cancer Center, leads this phase III trial that tests if gabapentin can prevent the need for opiate pain medication for mouth sores (oral mucositis) in patients undergoing treatment with chemotherapy and radiation for squamous cell carcinoma of the head and neck region.

The trial opened on June 5, 2025, with the ClinicalTrials.gov Identifier: NCT06992427. To learn more about the trial, visit here.

 


Read more articles in this issue: